North Star Asset Management Inc. Has $12.58 Million Holdings in Prestige Consumer Healthcare Inc. $PBH

North Star Asset Management Inc. grew its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 5.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 203,877 shares of the company’s stock after acquiring an additional 10,887 shares during the quarter. North Star Asset Management Inc.’s holdings in Prestige Consumer Healthcare were worth $12,577,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in Prestige Consumer Healthcare by 4.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company’s stock worth $161,723,000 after purchasing an additional 119,459 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in Prestige Consumer Healthcare by 1.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock worth $98,776,000 after purchasing an additional 21,085 shares during the last quarter. Bank of America Corp DE increased its position in Prestige Consumer Healthcare by 19.1% in the 2nd quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock worth $57,601,000 after purchasing an additional 115,459 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in Prestige Consumer Healthcare by 10.2% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock worth $40,147,000 after purchasing an additional 60,496 shares during the last quarter. Finally, Raymond James Financial Inc. increased its position in Prestige Consumer Healthcare by 15.7% in the 3rd quarter. Raymond James Financial Inc. now owns 637,932 shares of the company’s stock worth $39,807,000 after purchasing an additional 86,373 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, VP Jeffrey Zerillo sold 1,207 shares of the stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the sale, the vice president owned 42,820 shares in the company, valued at $2,354,671.80. This represents a 2.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on PBH shares. Jefferies Financial Group dropped their target price on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Friday, January 30th. Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Zacks Research downgraded Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Canaccord Genuity Group decreased their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Finally, Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $70.75.

Prestige Consumer Healthcare Stock Performance

PBH opened at $48.02 on Friday. The company has a market cap of $2.27 billion, a PE ratio of 12.28, a price-to-earnings-growth ratio of 1.54 and a beta of 0.40. The stock has a 50-day moving average of $55.97 and a 200-day moving average of $60.90. Prestige Consumer Healthcare Inc. has a 52-week low of $42.62 and a 52-week high of $87.12. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.25 and a current ratio of 3.57.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The company had revenue of $281.62 million for the quarter, compared to the consensus estimate of $293.64 million. During the same quarter last year, the company posted $1.32 EPS. The business’s revenue was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).